Physician Assistant Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yelena Vevitsis

Dermatology Brooklyn, NY Physician Assistant

NPI 1013248103 CMS profile 506099

1220 Avenue P, Brooklyn, NY 11229

Open in the dashboard

General payments

$6,693

324 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yelena Vevitsis of Brooklyn, NY is reported in the CMS Open Payments database as having received $6,693 across 324 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,324 60
2024 General $1,570 70
2023 General $1,562 80
2022 General $1,014 55
2021 General $1,185 57
2019 General $37 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yelena Vevitsis
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Yelena Vevitsis were reported at $1,324. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Yelena Vevitsis Dermatology median Middle half National median
2019 $37 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $1,185 $377 $108–$1,108 $132
2022 $1,014 $514 $143–$1,391 $149
2023 $1,562 $607 $159–$1,674 $160
2024 $1,570 $751 $204–$1,903 $164
2025 $1,324 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Biotech, Inc. $1,352 60 payments
  2. AbbVie, Inc. $1,255 63 payments
  3. Incyte Corporation $864 45 payments
  4. Lilly USA, LLC $449 21 payments
  5. Sun Pharmaceutical Industries Inc. $367 22 payments
  6. Regeneron Healthcare Solutions, Inc. $329 14 payments
  7. Dermavant Sciences, Inc. $285 11 payments
  8. LEO Pharma Inc. $208 10 payments
  9. Arcutis Biotherapeutics, Inc. $189 9 payments
  10. Genzyme Corporation $182 8 payments
  11. Other $1,214 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,376 320 payments
  2. Education $317 4 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $1,286 56 payments
  2. OPZELURA $864 45 payments
  3. SKYRIZI Immunology $813 35 payments
  4. TALTZ $334 16 payments
  5. VTAMA $308 12 payments
  6. RINVOQ $250 20 payments
  7. DUPIXENT $230 10 payments
  8. SKYRIZI Immunology $200 9 payments
  9. ADBRY $172 8 payments
  10. Odomzo $160 11 payments
  11. Other $3,085 159 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

324 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record